Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc.

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly and Company (LLY) announced the successful completion of its acquisition of Verve Therapeutics. (VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for ...

INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for ...

Key Takeaways Shares of Verve Therapeutics soared 75% Tuesday as Eli Lilly said it would acquire the gene-editing startup.The deal values Verve at about $1.3 billion, with some of Eli Lilly's ...

Verve Therapeutics VERV signed a definitive agreement with pharma bigwig Eli Lilly LLY.Per the terms, the pharma giant will acquire all outstanding shares of VERV for $10.50 per share in cash ...

Eli Lilly to buy Verve Therapeutics for $10.50 per share, with total potential payout up to $13.50 per share. The $1.3 billion deal offers a 113% premium to Verve’s 30-day average stock price.

Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to purchase all of the ...

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics ...

INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for ...